Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Rating of “Buy” by Analysts
Shares of Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) have been assigned a consensus rating of “Buy” from the seven ...
Open Lending Co. (NASDAQ:LPRO) Given Average Recommendation of “Moderate Buy” by Analysts
Open Lending Co. (NASDAQ:LPRO – Get Free Report) has received a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the company, Marketbeat.com reports. Three ...
Korro Bio price target lowered to $95 from $105 at RBC Capital
RBC Capital lowered the firm’s price target on Korro Bio (KRRO) to $95 from $105 and keeps an Outperform rating on the shares. The firm notes ...
Is Korro Bio (NASDAQ:KRRO) In A Good Position To Invest In Growth?
So, the natural question for Korro Bio (NASDAQ:KRRO) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual (negative) free cash ...
Korro Reports Full Year 2024 Financial Results and Provides Business Updates
Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim ...
The Manila Times2d
Matador Technologies Inc. to List on OTCQB
Matador Technologies Inc. ('Matador” or the 'Company”) (TSXV: MATA) is pleased to announce that it has received approval to list its common shares on the OTC Markets under the ticker symbol ...
Korro Bio, Inc.: KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on ...
Korro Bio gets Orphan Drug Designation from FDA for its genetic disorder treatment
Korro Bio received U.S. FDA's orphan drug designation for investigational medicine KRRO-110 to treat Alpha-1 Antitrypsin ...
Korro Bio's KRRO-110 Gets FDA Orphan Drug Designation
Korro Bio disclosed that the Food and Drug Administration granted orphan drug designation to its potential genetic disorder drug KRRO-110. Shares rose 17.6% to $29 in premarket trading. The stock is ...